Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records

por Kolaczynski, Wlodzimierz M., Hankins, Matthew, Ong, Siew H., Richter, Hartmut, Clemens, Andreas, Toussi, Massoud
Publicado 2016

ArhGAP9, a novel MAP kinase docking protein, inhibits Erk and p38 activation through WW domain binding

por Ang, Boon K, Lim, Chun Y, Koh, Sharon S, Sivakumar, Neelamegam, Taib, Shahrizan, Lim, Kim B, Ahmed, Sohail, Rajagopal, Guna, Ong, Siew H
Publicado 2007